Buy KALGARY SIBUTRAMINE HCL 15MG BY TAGMA PHARMA 7 CAPSULES / STRIP

Product Details: Kalgary (Sibutramine HCL) 15mg by Tagma Pharma / Pack (14 Capsules)

Composition: Each Capsule contains Sibutramine hydrochloride monohydrate 10 & 15mg

Prescribing Information: Kalgary (Sibutramine HCL) 15mg by Tagma Pharma belongs to Sibutramine class which is a weight reducer. Sibutramine is a neurotransmitter reuptake inhibitor that inhibits the reuptake serotonin (by 73%), norepinephrine (by 54%). It helps enhance Satiety. Sibutramine is well absorbed from the GI-Tract (77%), Undergoes a first-pass metabolism reducing its bioavailability. It reaches its peak plasma level after 1 hour. Is metabolized by cytochrome-P450-isoenzyme resulting in 2 active primary and secondary amines (called active metabolites 1 and 2). Peak plasma concentrations of active metabolites 1 and 2 are reached after 3 to 4 hours. Kalgary (Sibutramine HCL) 15mg by Tagma Pharma is excreted 85% in urine and 15%faeces. Although predominantly inactive metabolites are excreted by the renal route, caution is recommended when treating patients with reduced renal function. Initial dosage is 10mg once daily. In patients with inadequate response to Kalgary (Sibutramine HCL) 15mg by Tagma Pharma at 10mg the dose may be increased to 15mg once daily.

Renal Insufficiency

Illumination of inactive hydroxyl metabolites, which are renally excreted, may be affected in this population.

Indications

• Nobese is indicated for management of obesity including weight loss and weight maintenance When used in conjunction with a reduce calorie diet.
• In patients with an initial body mass index <30kg/m or <27kg/m in the presence of oter risk factors (hypertension, disbetes, dislipidemia).

Dosage

The recommended initial oral dose of nobese is 10 mg capsule once daily with or without food. If there is inadequate weight loss (i.e. <20kg) the dose may be increased to 15 mg provided 10 mg was well tolerated. The 5 mg dose should be reserved for patients who do not tolerate the 10 mg dose.

Nobese treatment should not be given for longer than 1 year. Maximum weight loss (5%-10% of initial body weight) is usually achieved within six months. Nobese must be discontinued in patients who have not responded adequately, i.e. whose weight loss stabilizes at less than 5% of their initial body weight or whose weight loss within three months after starting therapy has been less than 5% of their initial body weight. Nobese should not be continued in patients who regain 3kg or more after previously achieved weight loss.

Adverse Reaction

Most of the adverse reactions of Nobese occur at the start of the treatment (1^st 4 weeks). There severity and frequency diminishes over time. The frequently observed events are;

• Dry mouth
• Headache
• Insomnia
• Constipation
• Diarrhea
• Back pain
• Increased apatite
• Dizziness
• Influenza like symptoms
• Rhinitis

Less Frequent Adverse Reactions with Nobese

• Dyspepsia
• Nausea
• Dysmenorrhea
• Increased sweating and thirst
• Oedema
• Parathesia
• Taste perversion
• Drossiness
• Skin rashes
• Palpitation
• Vasodilatation
• Anxiety
• Nervousness
• Depression                                                                          Buy KALGARY SIBUTRAMINE HCL 15MG